Impact of medical therapy on patients with Crohn's disease requiring surgical resection

World Journal of Gastroenterology

Volumn 20, Issue 33, 2014, Pages 11808-11814

  Fu, Y T Nancy ^a   Hong, Thomas ^a   Round, Andrew ^b   Bressler, Brian ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Gastrointestinal Research Institute   (Canada)

Author keywords

Anti tumor necrosis factor; Biologics; Crohn's disease; Immunomodulators; Inflammatory bowel disease; Medication; Phenotype; Surgery

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR; BIOLOGICAL PRODUCT; GASTROINTESTINAL AGENT; IMMUNOLOGIC FACTOR;

ADULT; AGE; ARTICLE; COLON RESECTION; COLON STENOSIS; CONTROLLED STUDY; CROHN DISEASE; FEMALE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PHARMACEUTICAL CARE; RETROSPECTIVE STUDY; SURGICAL PATIENT; TIME TO TREATMENT; ABDOMINAL SURGERY; ADOLESCENT; ADVERSE EFFECTS; CANADA; CHI SQUARE DISTRIBUTION; DRUG COMBINATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHENOTYPE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TERTIARY CARE CENTER; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; BIOLOGICAL PRODUCTS; BRITISH COLUMBIA; CHI-SQUARE DISTRIBUTION; CROHN DISEASE; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TERTIARY CARE CENTERS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84909608171     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i33.11808     Document Type: Article

References (35)

1. Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001; 49: 777-782 [PMID: 11709511 DOI: 10.1136/gut.49.6.777]
2. Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, Gendre JP. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244-250 [PMID: 12131607 DOI: 10.1097/00054725-200207000-00002]
3. Peyrin-Biroulet L, Loftus EV, Colombel JF, Sandborn WJ. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol 2010; 105: 289-297 [PMID: 19861953 DOI: 10.1038/ajg.2009.579]
4. Bouguen G, Peyrin-Biroulet L. Surgery for adult Crohn' s disease: what is the actual risk? Gut 2011; 60: 1178-1181 [PMID: 21610273 DOI: 10.1136/gut.2010.234617]
5. Silverstein MD, Loftus EV, Sandborn WJ, Tremaine WJ, Feagan BG, Nietert PJ, Harmsen WS, Zinsmeister AR. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999; 117: 49-57 [PMID: 10381909 DOI: 10.1016/S0016-5085(99)70549-4]
6. Burger D, Travis S. Conventional medical management of inflammatory bowel disease. Gastroenterology 2011; 140: 1827-1837.e2 [PMID: 21530749 DOI: 10.1053/j.gastro.2011.02.045]
7. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van de Mierop FJ, Coche JC, van der Woude J, Ochsenkühn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P, Feagan BG, Hommes D. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-667 [PMID: 18295023 DOI: 10.1016/S0140-6736(08)60304-9]
8. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549 [PMID: 12047962 DOI: 10.1016/S0140-6736(02)08512-4]
9. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-885 [PMID: 14985485 DOI: 10.1056/NEJMoa030815]
10. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-333; quiz 591 [PMID: 16472588 DOI: 10.1053/j.gastro.2005.11.030]
11. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56: 1232-1239 [PMID: 17299059 DOI: 10.1136/gut.2006.106781]
12. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65 [PMID: 17241859 DOI: 10.1053/j.gastro.2006.11.041]
13. Colombel JF, Schwartz DA, Sandborn WJ, Kamm MA, D'Haens G, Rutgeerts P, Enns R, Panaccione R, Schreiber S, Li J, Kent JD, Lomax KG, Pollack PF. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 2009; 58: 940-948 [PMID: 19201775 DOI: 10.1136/gut.2008.159251]
14. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-753 [PMID: 16698746 DOI: 10.1136/gut.2005.082909]
15. Nguyen GC, Nugent Z, Shaw S, Bernstein CN. Outcomes of patients with Crohn's disease improved from 1988 to 2008 and were associated with increased specialist care. Gastroenterology 2011; 141: 90-97 [PMID: 21458455 DOI: 10.1053/j.gastro.2011.03.050]
16. Bernstein CN, Loftus EV, Ng SC, Lakatos PL, Moum B. Hospitalisations and surgery in Crohn's disease. Gut 2012; 61: 622-629 [PMID: 22267595 DOI: 10.1136/gutjnl-2011-301397]
17. Vind I, Riis L, Jess T, Knudsen E, Pedersen N, Elkjaer M, Bak Andersen I, Wewer V, Nørregaard P, Moesgaard F, Bendtsen F, Munkholm P. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol 2006; 101: 1274-1282 [PMID: 16771949 DOI: 10.1111/j.1572-0241.2006.00552.x]
18. Jess T, Riis L, Vind I, Winther KV, Borg S, Binder V, Langholz E, Thomsen OO, Munkholm P. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis 2007; 13: 481-489 [PMID: 17206705 DOI: 10.1002/ibd.20036]
19. Ramadas AV, Gunesh S, Thomas GA, Williams GT, Hawthorne AB. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 2010; 59: 1200-1206 [PMID: 20650924 DOI: 10.1136/gut.2009.202101]
20. Lakatos PL, Golovics PA, David G, Pandur T, Erdelyi Z, Horvath A, Mester G, Balogh M, Szipocs I, Molnar C, Komaromi E, Veres G, Lovasz BD, Szathmari M, Kiss LS, Lakatos L. Has there been a change in the natural history of Crohn' s disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009. Am J Gastroenterol 2012; 107: 579-588 [PMID: 22233693 DOI: 10.1038/ajg.2011.448]
21. Herrinton LJ, Liu L, Fireman B, Lewis JD, Allison JE, Flowers N, Hutfless S, Velayos FS, Abramson O, Altschuler A, Perry GS. Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005. Gastroenterology 2009; 137: 502-511 [PMID: 19445944 DOI: 10.1053/j.gastro.2009.04.063]
22. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005; 54: 237-241 [PMID: 15647188 DOI: 10.1136/gut.2004.045294]
23. Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn' s disease. Cochrane Database Syst Rev 2010; (6 ): CD000545 [PMID: 20556747 DOI: 10.1002/14651858.CD000545.pub3]
24. Khan KJ, Dubinsky MC, Ford AC, Ullman TA, Talley NJ, Moayyedi P. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 630-642 [PMID: 21407186 DOI: 10.1038/ajg.2011.72]
25. Peyrin-Biroulet L, Oussalah A, Williet N, Pillot C, Bresler L, Bigard MA. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut 2011; 60: 930-936 [PMID: 21228429 DOI: 10.1136/gut.2010.227884]
26. Chatu S, Subramanian V, Saxena S, Pollok RC. The role of thiopurines in reducing the need for surgical resection in Crohn's disease: a systematic review and meta-analysis. Am J Gastroenterol 2014; 109: 23-34; quiz 35 [PMID: 24322839 DOI: 10.1038/ajg.2013.402]
27. Domènech E, Zabana Y, Garcia-Planella E, López San Román A, Nos P, Ginard D, Gordillo J, Martínez-Silva F, Beltrán B, Mañosa M, Cabré E, Gassull MA. Clinical outcome of newly diagnosed Crohn's disease: a comparative, retrospective study before and after infliximab availability. Aliment Pharmacol Ther 2010; 31: 233-239 [PMID: 19832727 DOI: 10.1111/j.1365-2036.2009.04170.x]
28. Sands BE, Arsenault JE, Rosen MJ, Alsahli M, Bailen L, Banks P, Bensen S, Bousvaros A, Cave D, Cooley JS, Cooper HL, Edwards ST, Farrell RJ, Griffin MJ, Hay DW, John A, Lidofsky S, Olans LB, Peppercorn MA, Rothstein RI, Roy MA, Saletta MJ, Shah SA, Warner AS, Wolf JL, Vecchio J, Winter HS, Zawacki JK. Risk of early surgery for Crohn' s disease: implications for early treatment strategies. Am J Gastroenterol 2003; 98: 2712-2718 [PMID: 14687822 DOI: 10.1111/j.1572-0241.2003.08674.x]
29. Costa J, Magro F, Caldeira D, Alarcão J, Sousa R, Vaz-Carneiro A. Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2013; 19: 2098-2110 [PMID: 23860567 DOI: 10.1097/MIB.0b013e31829936c2]
30. Slattery E, Keegan D, Hyland J, O'donoghue D, Mulcahy HE. Surgery, Crohn's disease, and the biological era: has there been an impact? J Clin Gastroenterol 2011; 45: 691-693 [PMID: 21135702 DOI: 10.1097/MCG.0b013e318201ff96]
31. Lazarev M, Ullman T, Schraut WH, Kip KE, Saul M, Regueiro M. Small bowel resection rates in Crohn's disease and the indication for surgery over time: experience from a large tertiary care center. Inflamm Bowel Dis 2010; 16: 830-835 [PMID: 19798731 DOI: 10.1002/ibd.21118]
32. Adamiak T, Walkiewicz-Jedrzejczak D, Fish D, Brown C, Tung J, Khan K, Faubion W, Park R, Heikenen J, Yaffee M, Rivera-Bennett MT, Wiedkamp M, Stephens M, Noel R, Nugent M, Nebel J, Simpson P, Kappelman MD, Kugathasan S. Incidence, clinical characteristics, and natural history of pediatric IBD in Wisconsin: a population-based epidemiological study. Inflamm Bowel Dis 2013; 19: 1218-1223 [PMID: 23528339 DOI: 10.1097/MIB.0b013e318280b13e]
33. Piekkala M, Pakarinen M, Ashorn M, Rintala R, Kolho KL. Long-term outcomes after surgery on pediatric patients with Crohn disease. J Pediatr Gastroenterol Nutr 2013; 56: 271-276 [PMID: 23114471 DOI: 10.1097/MPG.0b013e318279871c]
34. Abraham BP, Mehta S, El-Serag HB. Natural history of pediatric-onset inflammatory bowel disease: a systematic review. J Clin Gastroenterol 2012; 46: 581-589 [PMID: 22772738 DOI: 10.1097/MCG.0b013e318247c32f]
35. Solberg IC, Cvancarova M, Vatn MH, Moum B. Risk matrix for prediction of advanced disease in a population-based study of patients with Crohn's Disease (the IBSEN Study). Inflamm Bowel Dis 2014; 20: 60-68 [PMID: 24280875 DOI: 10.1097/01.MIB.0000436956.78220.67]